Epoxyeicosatrienoic Acids Attenuate Reactive Oxygen Species level, Mitochondrial Dysfunction, Caspase Activation and Apoptosis in Carcinoma Cells Treated with Arsenic Trioxide

Liu Liu, Chen Chen, Wei Gong, Yuanjing Li, Matthew L. Edin, Darryl C. Zeldin and Dao Wen Wang

Department of Internal Medicine and Gene Therapy Center, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, P.R. China (L. L., C. C., W. G., Y. L., D. W. W.); and Division of Intramural Research, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC 27709 USA (M. L. E., D. C. Z.)
Running Title: EETs, ROS and Apoptosis

To whom correspondence should be addressed:
Dao Wen Wang, MD, PhD
Department of Internal Medicine
Tongji Hospital, Tongji Medical College
Huazhong University of Science and Technology
1095# Jiefang Ave.
Wuhan, 430030, P.R.China
Tel and Fax: (86-27)8366-3280
E-mail: dwwang@tjh.tjmu.cn

Number of text pages: 30
Number of tables: 0
Number of figures: 6
Number of references: 44
Number of words in the Abstract: 173
Number of words in Introduction: 401
Number of words in Discussion: 1163

Abbreviations – EETs, epoxyeicosatrienoic acids; CYP, cytochrome P450; AA, arachidonic acid; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; RT-PCR, Reverse transcriptase-polymerase chain reaction; PVDF, polyvinylidene difluoride; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ERK, extracellular signal-regulated kinase; ATO, arsenic trioxide; ROS, reactive oxygen species; DCFH-DA, 2,7-dichlorodihydrofluorescein diacetate; SODs, superoxide dismutases; SRB, Sulforhodamine B; TCA, trichloroacetic acid
Abstract

Epoxyeicosatrienoic acids (EETs) and the P450 epoxygenase CYP2J2 promote tumorogenesis in vivo and in vitro via direct stimulation of tumor cell growth and inhibition of tumor cell apoptosis. Herein, we describe a novel mechanism of inhibition of tumor cell apoptosis by EETs. In Tca-8113 cancer cells, the anti-leukemia drug arsenic trioxide (ATO) led to generation of reactive oxygen species (ROS), impaired mitochondrial function and induced apoptosis. 11,12-EET pretreatment increased expression of the anti-oxidant enzymes superoxide dismutase and catalase, and inhibited ATO-induced apoptosis. 11,12-EET also prevented the ATO-induced activation of p38 MAPK, JNK, and caspase-3 and -9. Therefore, 11,12-EET-pretreatment attenuated the ROS generation, loss of mitochondrial function, and caspase activation observed after ATO treatment. Moreover, the CYP2J2 specific inhibitor C26 enhanced arsenic cytotoxicity to a clinically relevant concentration of ATO (1-2 µM). Both the thiol-containing antioxidant, N-acetyl-cysteine and 11,12-EET reversed the synergistic effect of the two agents. Taken together, these data indicate that 11,12-EET inhibits apoptosis induced by ATO through a mechanism that involves induction of anti-oxidant proteins and attenuation of ROS-mediated mitochondrial dysfunction.

Key Words: Epoxyeicosatrienoic acids (EETs); Cytochrome P450 epoxygenase; reactive oxygen species; anti-oxidation
Introduction

Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to four regioisomeric cis-epoxyeicosatrienoic acids (EETs): 5,6-, 8,9-, 11,12-, and 14,15-EET (Zeldin, 2001). EETs possess multiple biological effects in the cardiovascular and renal systems, including anti-inflammatory (Node et al., 1999) and angiogenic (Michaelis et al., 2003; Wang et al., 2005) effects on endothelial cells, inhibition of vascular smooth muscle cell migration (Sun et al., 2002), and inhibition of apoptosis (Chen et al., 2001; Yang et al., 2007). Recently, we showed that CYP2J2, a human CYP epoxygenase that generates all four EETs, is highly expressed in several human organ tumors such as the cancers of esophagus, liver, breast, lung and colon (Jiang et al., 2005). In addition, CYP2J2-derived EETs stimulate tumor cell proliferation, protect against apoptosis and promote tumor invasion and metastasis in vitro and in vivo (Jiang et al., 2007).

The term reactive oxygen species (ROS) refers to highly reactive species that are oxygen metabolites or derivates. These include superoxide anions (O$_2^-$), hydrogen peroxide (H$_2$O$_2$), hydroxyl radicals (·OH), singlet oxygen (¹O$_2$), and nitric oxide (NO). Several enzymes and the mitochondrial electron transport chain naturally produce ROS, and ROS production correlates with normal cell proliferation and signal transduction (D’Autreaux and Toledano, 2007; Valko et al., 2007). ROS have been implicated in the etiology of a wide range of human diseases including cancers (Valko et al., 2007). Extensive evidence indicates that ROS plays a critical role in tumor cell apoptosis whether induced by ischemia, drugs, or receptor mediated factors (Pelicano et al., 2004; Engel and Evens, 2006; Orrenius, 2007; Ryter et al., 2007).

Arsenic trioxide (As$_2$O$_3$, ATO) was first used clinically to induce differentiation and apoptosis of all-trans-retinoic acid-resistant acute promyelocytic leukemia (Chen
et al., 1997; Soignet et al., 1998). With accumulating experience and enhanced knowledge of the molecular actions of ATO and ROS, treatment of patients with ATO has been extended to solid tumors (Gazitt and Akay, 2005). ATO exerts its effect mainly by elevating intracellular ROS, disrupting cellular redox equilibrium and inducing mitochondrial dysfunction (Perkins et al., 2000; Mahieux et al., 2001).

Our previous studies suggest that EETs inhibit tumor necrosis factor (TNF)-α-induced apoptosis through upregulation of the anti-apoptotic proteins Bcl-2 and Bcl-xl and down-regulation of the pro-apoptotic protein Bax. However, it remains unknown how EETs modulate mitochondrial pathways that lead to apoptosis. In the present study, we extend our previous findings by elucidating the relationship between EETs and mitochondrial dysfunction induced by ATO.
Materials and methods

Experimental Reagents: Cell culture medium (DMEM) and fetal bovine serum were from Invitrogen (Carlsbad, CA). 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA), Sulforhodamine B (SRB), JNK inhibitor (SP600125) and ERK Inhibitor (PD98059) were from Sigma-Aldrich (St. Louis, MO). 8,9-EET, 11,12-EET and 14,15-EET were from Cayman Chemical Company (Ann Arbor, MI). p38 inhibitor (SB203580) was from Promega (Madison, WI). Antibodies against CYP2J2 and CypD were purchased from Abcam Inc. (Cambridge, MA). Antibodies against cytochrome c, superoxide dismutases (SODs), catalase and β-actin were from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against ERK, p-ERK, P38, p-P38, JNK and p-JNK were purchased from Cell Signaling Technology (Beverly, MA). The CYP2J2-specific inhibitor C26 was synthesized as described (Chen et al., 2009). siRNAs were synthesized by Ribobio Co. (Guangzhou, China). All other reagents were purchased from standard commercial suppliers unless otherwise indicated.

Cell culture: Tca-8113 cells and HepG2 cells were obtained from the American Type Culture Collection (Manassas, VA) and maintained as recommended. Cells were cultured in DMEM, adjusted to contain 4 mmol/L L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10% FBS, 100 units/mL penicillin and 65 units/mL streptomycin. All cell cultures were maintained at 37°C in constant humidified incubator containing 95% air/5% CO₂ atmosphere.

Transfection: Transfection was performed with Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions with cells plated in 6-well plates were at a density of approximately 1 x 10⁶ cells/well. The cells were harvested 24 hours after transfection with siRNAs.

Cell cytotoxicity assay: Sulforhodamine B (SRB) was used to assess growth
inhibition. This colorimetric assay estimates cell number indirectly by staining total cellular protein with SRB. Briefly, cells were collected by trypsinization, counted, plated at a density of 5,000 cells/well in 96-well flat-bottomed microtiter plates (100 μl/well), and exposed as indicated. After exposure, the medium was removed, cells were fixed with 20% (w/v) trichloroacetic acid (TCA) at 4°C for 1 h, and stained for 30 min with 0.4% (w/v) SRB dissolved in 1% acetic acid. Wells were washed five times with 1% acetic acid and the protein-bound dye was solubilized with 10 mM Tris base (pH 10). The optical density (OD) of cells was determined at a wavelength of 540 nm using a colorimetric plate reader. Data is represented as a percentage of control cells.

**Reactive oxygen species detection:** H$_2$O$_2$ production was determined using reagents and protocols provided in the Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Molecular Probes, Eugene, OR). Briefly, Amplex Red (50 μM) and horseradish peroxidase (0.1 U/ml) were added to the cellular samples. Fluorescence readings were made in a 96-well plate at ex530 nm and em590 nm. Background fluorescence, measured in the absence of cells, was subtracted from experimental values. To confirm hydrogen peroxide specificity, parallel samples were coincubated with 1000 U/ml catalase and the specificity of the reaction was obtained by subtracting the amount of H$_2$O$_2$ produced in the presence of catalase from that in the absence of catalase. H$_2$O$_2$ concentration was calculated using a standard curve.

Alternatively, DCFH-DA was used as an ROS capturing reagent using methods described previously. DCFH-DA becomes deacetylated intracellularly by nonspecific esterases, and is furthered oxidized by ROS to the fluorescent compound DCF. Cells were incubated with 10 μM DCFH-DA at 37°C for 20 min. Immediately after staining, DCF fluorescence was detected by inverted epifluorescence microscope or by flow cytometry (Zmijewski et al., 2005).
Mitochondrial transmembrane potential measurement: To determine the mitochondrial membrane potential of cells, a membrane potential–sensitive fluorescent probe, JC-1, (Stratagene, La Jolla, CA) was used. JC-1 is a cationic carbocyanine dye that presents itself as green fluorescent monomers at low concentration and yellow-red fluorescent J-aggregates when concentrated in functional mitochondria. Briefly, cells were plated into 35 mm glass bottom microwell dishes. After incubation, the cells were loaded with 10 µmol/L JC-1 for 30 minutes at 37°C, washed and viewed using an epifluorescence microscope with a blue excitation filter at 488 nm or a green excitation filter at 543 nm, to allow for the visualization of the green and yellow-red fluorescence, respectively. Both the yellow-red J-aggregates and the green monomer can be viewed with a “double-bandpass” filter designed to simultaneously detect fluorescein and rhodamine.

Caspase activity analysis: Caspase-3 and -9 activities were measured by colorimetric assays (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. Cells were lysed in chilled lysis buffer after treatment with various agents for the indicated times. Cell lysates were centrifuged at 15,000 x g for 10 min, and the supernatants were added to 50 µl of 2X reaction buffer and 5µl of 5 mM caspase-9 or 1 mM caspase-3 substrates. After incubation at 37°C for 1 h, absorbance was read at a wavelength of 405 nm.

Evaluation of apoptosis: According to previous publications (Han et al., 2009); (Han et al., 2010) and our pretest results, we treated cells with ATO with or without 11,12-EET for various times and doses as indicated. Flow cytometric assays with Annexin V and propidium iodide staining (BD Pharmingen, San Diego, CA) were done as previously described (Jiang et al., 2005).

Western blotting: Western blotting was performed as described previously
Briefly, cell lysates were prepared by extracting proteins with lysis buffer [40 mmol/L Tris-Cl (pH 8.0), 120 mmol/L NaCl, and 0.1% NP40] supplemented with protease and phosphatase inhibitors. Proteins were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA). The membranes were blocked with 5% nonfat dry milk in Tris-buffered saline and then incubated with primary antibodies overnight at 4°C. Blots were developed with peroxidase-conjugated secondary antibody, and proteins were visualized by enhanced chemiluminescence (Pierce, Rockford, IL).

**SOD and catalase activity assays:** Total SOD and catalase activity were measured with colorimetric kits (Jiancheng Bioengineering Institute, Nanjing, China). The SOD activity was determined by hydroxylamine assay-developed from xanthine oxidase assay. Briefly, cells were sonicated and the lysates were reacted with reaction buffer and color developing reagent according to the manufacturer’s instructions. The superoxide can oxidize hydroxylamine to form nitrite, which colors amaranth by the color developing agent, and it can be assayed by spectrophotometer. The SOD detected in the sample could specific inhibition on the formation of superoxide anion and the quantity of produced nitrite is reduced. So the absorbance of test tube will be lower than that of control tube, we can calculate the activity of SOD in the sample with the formula. After incubation at 37°C for 40 min, absorbance was read at a wavelength of 550 nm, and OD value was used for calculating SOD activity with the formula according to manufacture’s instructions. The catalase activity was assayed likewise; cell lysates were reacted with reagents provided by the kit. The methodology assay catalase activity is based on the reaction of the enzyme in the presence of an optimal concentration of H$_2$O$_2$. The rate of dismutation of hydrogen peroxide to water and molecular oxygen is proportional to the concentration of
catalase. Therefore, the sample containing catalase is incubated in the presence of a known concentration of hydrogen peroxide. After incubation for exactly one minute, the reaction is quenched with ammonium molybdate. The amount of hydrogen peroxide remaining in the reaction mixture is then formation of its stable colored complex with ammonium molybdate and the complex is measured at 405nm. Tone unit of catalase activity was defined as the amount enzyme that will decompose 1 μmol hydrogen peroxide in one second per milligram of protein.

**Statistical analysis:** All data are presented as mean ± SEM. Significant differences between groups were determined using the unpaired student’s t-test. A p-value of less than 0.05 from two tailed student t-test analysis was used to indicate statistical significance. All the figures shown are representative of at least three independent experiments.
Results

11,12-EET decreases ATO-induced increase in ROS level in tumor cells.

Treatment of Tca-8113 cells with 10 µM ATO for 2 hours led to a significant increase in ROS production. The effects were dose-dependent in the range of 1 µM-10 µM (Supplemental Figure 1). To test whether EETs increases the capacity of tumor cells to scavenge ROS, Tca-8113 cells were incubated for 24 hours with 100 nM 8,9-EET, 11,12-EET or 14,15-EET prior to treatment with ATO. Pre-incubation with EETs significantly lowered ATO–induced increase in ROS level in these cells, but EET alone did not show the effect (Fig. 1A). We further confirmed this result in additional experiments and results showed that 11,12-EET reduced ATO induced increase in ROS level measured by flow cytometry (Fig. 1B and 1C), and addition of CYP2J2 specific inhibitor-C26 significantly enhanced the effect of ATO (Supplemental Figure 2). Since DCFH is limited by its lack of specificity and tendency to be spontaneously photooxidized, we performed more rigorous experiments to measure the intracellular hydrogen peroxide production via extracellular leakage of H₂O₂ using Amplex Red method. Likewise, EETs reduced ATO induced ROS level measured by Amplex Red method (Fig. 1D). None of isoforms of EETs treated alone altered the ROS level significantly as shown in Fig. 1E. In the subsequent investigations, we used 11,12-EET, which is a potent and abundant EET in human body.

11,12-EET upregulates expression and activity of antioxidant enzymes.

EETs have been shown to protect against injury following ischemia/reperfusion in endothelial cells (Wang et al., 2005), where ROS-induced lipid peroxidation causes significant cytotoxicity (Valko et al., 2007). Therefore, we hypothesized that antioxidant enzymes may account for the beneficial actions of EETs. We investigated the regulation of antioxidant enzyme expression by 11,12-EET in tumor cells. As
shown in Fig. 2A, 11,12-EET increased ZnCu-SOD, Mn-SOD and catalase protein levels in a time- and dose-dependent manner. Moreover, incubation of Tca-8113 cells with 100 nM EET for 12h increased both total SOD and catalase activity (Fig. 2B).

**11,12-EET attenuates mitochondrial trans-membrane potential collapse and caspase activation after treatment of tumor cells with ATO.** Oxidative damage plays an important role in the anti-cancer effects of ATO (Chen et al., 1998). Therefore, we examined whether EET-induced changes in SOD and catalase expression/activity could significantly affect ROS levels and apoptotic induction by ATO in tumor cells.  Apoptotic cells were indentified by Annexin V staining after 24 hours treatment with ATO with/without 11,12-EET. As shown in Figs. 3A and 3B, 11,12-EET significantly attenuated ATO-induced apoptosis.

ATO may also cause a collapse of the mitochondrial trans-membrane potential ($\Delta \Psi m$) prior to induction of apoptosis (Mahieux et al., 2001). $\Delta \Psi m$ was determined by JC-1 staining as shown in Fig. 3C. In cells with normal mitochondrial function, membrane potential–driven accumulation of these dyes results in the formation of yellow-red fluorescent J-aggregates as shown in the control panel. In cells treated with ATO, the green mitochondria stained with JC-1 dye indicate depressed $\Delta \Psi m$. Importantly, 11,12-EET co-treatment prevented the $\Delta \Psi m$ collapse caused by ATO. Arsenic-induced apoptosis involves the mitochondrial pathway and activation of caspases-3 and -9. Coincident with changes in $\Delta \Psi m$, treatment of cells with ATO caused caspase activation, an effect that was partially inhibited by 11,12-EET (Fig. 3D). Cytochrome c release also participated in mitochondrial dysfunction. Consistent with the effects on caspase activities, ATO-induced cytochrome c release was partially reversed by 11,12-EET (Fig. 3E). EET alone, however, did not have effects on apoptosis, $\Delta \Psi m$ and cytochrome c release.
11,12-EET reverses ATO-induced activation of stress response kinases. Among the three MAP kinases (ERK, JNK and p38), JNK and p38 are important factors in apoptosis signaling and are sensitive to ROS levels (Kang and Lee, 2008b). Therefore, we investigated the effects of ATO and 11,12-EET on p38, JNK and ERK phosphorylation. Pre-incubation with 11,12-EET blocked ATO-induced phosphorylation and hence activation of p38 and JNK. However, the effect of 11,12-EET was reversed by upregulation of ROS through hydrogen peroxide administration (Fig. 4A and 4B). Furthermore, in order to figure out that whether MAPKs, induced by ATO and inhibited by 11, 12-EET, are partially responsible for caspase activation and apoptosis, we investigated the effects of ATO and 11,12-EET on apoptosis by using specific inhibitors, and results showed that EET and inhibitors of JNK and p38 inhibited ATO induced apoptosis (Fig. 4C-4F). Moreover, the effects of EET on p38, JNK phosphorylation and ROS production were determined with specific inhibitors, the results showed that EET partially decreased the phosphorylation and ROS generation induced by ATO, but MAPKs inhibitors did not influence ROS generation (Supplemental Figure 3). We also measured the ERK pathways in the same way, and found that ERK inhibitor blocked ERK phosphorylation induced by EETs. However, 10 uM ATO has no significant effect on ERK phosphorylation, and ERK inhibitor has no significant effect on ATO- and ATO+EET-induced apoptosis (Supplemental Figure 4). These data suggested that EET played an important role in cell apoptosis via p38 and JNK induced by ROS.

The CYP2J2-specific inhibitor C26 and ATO synergistically inhibit cell replication. As reported previously, HepG2 cells expressed less CYP2J2 than Tca-8113 cells (Jiang et al., 2005), we tried to find out the effects of endogenous CYP2J2 on apoptosis by comparing the responses of two cell lines to apoptosis. In
Tca-8113 cells, ATO (2 to 5 µM) and a CYP2J2 specific inhibitor, Compound 26 (C26, 0.1 to 1 µM), caused a slight reduction in the number of viable cells when used in low doses (Fig. 5A and 5B), more interestingly, HepG2 cells are more sensitive to ATO compared with Tca-8113 cells (Fig. 5B). Apoptosis assays also showed that C26 and ATO induced cell apoptosis in a dose-dependent manner (Supplemental Figure 5 and Supplemental Figure 6). Moreover, ROS production in HepG2 cells was significantly more than in Tca-8113 cells with or without ATO treatment (Supplemental Figure 7). Neither C26 treatment alone nor ATO treatment alone reduced the number of viable cells, however, co-treatment of 1µM C26 and 2 µM ATO reduced tumor cell viability. Both 11,12-EET and the antioxidant N-acetyl-L-cysteine (NAC) prevented this effect, suggesting that, by inhibiting EET synthesis, C26 enhanced the cytotoxicity of ATO through an ROS dependent manner (Fig. 5C).

CYP2J2 inhibition sensitizes tumor cells to ATO-induced ROS elevation and apoptosis. Exposure of Tca-8113 cells to C26 had minimal effect on cellular ROS levels. However, C26 had a synergistic effect with ATO on cellular ROS production. Pre-treatment of 11,12-EET or 2mM NAC for 24 hours partially abolished the elevation of ROS caused by ATO and C26 (Fig 6A). Similarly, co-treatment with C26 and ATO also increased cellular apoptosis compared to C26 or ATO alone and this apoptosis was also attenuated by pretreatment with 11,12-EET or NAC (Fig. 6B and 6C). In order to exclude the potential side-effect of C26, we employed CYP2J2 specific siRNA to knockdown the expression of endogenous CYP2J2 (Fig. 6D). Confirming drug selectivity, the addition of CYP2J2 specific siRNAs (100 nM) led to a similar result as C26 treatment (Fig. 6E and 6F).
Discussion

ATO disturbs the natural oxidation and reduction equilibrium which in turn increases cellular ROS. In the present study, we show for the first time that EETs attenuate arsenic-induced ROS generation in candidate tumor cells. It is now well established that the pro-apoptotic effect of ATO is mediated by ROS (Dai et al., 1999; Jing et al., 1999; Kang et al., 2004). Moreover, growing evidence suggests that mitochondrial dysfunction plays a key role in oxidative stress (Brookes et al., 2004; Hail, 2005), and that ROS generation further impairs mitochondrial electron transport and enhances more ROS production (Simon et al., 2000; Zorov et al., 2006). Consistent with these reports, our results indicate that EETs, through induction of SODs and catalase, reduce intracellular ROS level and attenuate several major apoptotic signaling events. These events include MAP Kinase activation, the collapse of the mitochondrial transmembrane potential, and the activation of caspase-3 and -9, which ultimately inhibit tumor cell apoptosis induced by ATO (scheme 1). This work extends our knowledge of the anti-apoptotic mechanism of EETs to the indirect suppression of ROS and mitochondrial damage in cells treated with ATO.

MAP kinases are essential factors in apoptosis signaling and become activated in response to cellular redox state (Herr and Debatin, 2001). ATO was able to activate the p38 (Verma et al., 2002) and JNK/ stress-activated protein kinase (Davison et al., 2004) in tumor cells, an effect known to be mediated by ROS (Kang and Lee, 2008a). In this study, the alleviation of ATO-induced p38, JNK activation by EET could be reversed by exogenous administration of H$_2$O$_2$, and p38 inhibitor, JNK inhibitor and ERK inhibitor showed their interaction effects with EET treatment, indicating that EETs altered MAPKs signaling in a ROS-dependent manner. The relationship between ROS generation, mitochondrial dysfunction and the p38
activation has been well examined. Herein, we demonstrated that EET altered the p38 and mitochondrial responses by reducing ROS levels. Reports show that in several leukemia cell lines, the p38 MAPK pathway acts as a negative regulator of ATO-induced apoptosis and inhibits malignant cell growth (Giafis et al., 2006). However, inhibition of p38 activation failed to protect cells from ATO-induced apoptosis in solid tumor cell lines (Yi et al., 2004). In contrast, p38 activation does account for the mitochondrial translocation of Bax and the phosphorylation of Bcl-2 in response to ATO (Kang and Lee, 2008b; Kang and Lee, 2008a). These data indicate that p38 activation by ATO plays different role in different tumor cell types and it may not be the major determinant in the course of apoptotic processes. For this reason, the significance of altered MAPK signaling pathways by EET in certain tumor cells remains to be investigated. We also found that ERK inhibition can block EET-induced ERK phosphorylation. However, ATO (10 μM) has neither significant effect on ERK phosphorylation, and ERK inhibitor has nor significant effect on ATO- and ATO+EET-induced apoptosis, suggesting ERK may not involve the ATO-related apoptosis.

CYP2J2 is a major enzyme found in extrahepatic tissue, with predominant expression in the cardiovascular system, including endothelial cells and cardiomyocytes (Node et al., 1999). In recent publications, we first demonstrated that CYP2J2 was overexpressed in various human solid cancers and human-derived cancer cell lines (Jiang et al., 2005). This study clearly illustrates that EETs up-regulate the expression and activity of two subtypes of SOD. This may be, at least in part, the underlying mechanism by which EETs increase ROS scavenging. However, there are also other possible mechanisms through which EETs may induce ROS scavenging. For example, EETs are reported to up-regulate heme oxygenase-1
(HO-1) in endothelial cells (Sacerdoti et al., 2007). Increased enzymatic activity of HO results in decreased oxidative stress and a lower rate of apoptosis (Jozkowicz et al., 2007).

That Tca-8113 cell are apparently less sensitive to ATO than other tumor cells may be due to a relatively high level of CYP2J2 expression compared with other tumor lines such as HepG2 (Jiang et al., 2005). EETs are involved in the apoptosis, cell cycle, cell adhesion, chromosome stability and DNA repair networks that are frequently affected in carcinogenesis (Croce, 2008). As shown in Figure 5B, HepG2 cell generate less EETs than Tca-8113 cell, which may result in lower anti-oxidant effects. Consistent with this hypothesis, we detect significantly more ROS in HepG2 cells than Tca-8113 cells, and HepG2 cells are more susceptible to apoptosis. Low ATO concentrations showed similar effects in Tca-8113 and HepG2, though differences were observed with increasing concentrations, which is consistent with our hypothesis (Figure 5B). The susceptibility of tumor cells to ATO is associated with the inherent cellular ROS level (Yi et al., 2002), and some compounds enhance the arsenic cytotoxicity via increasing intracellular ROS production (Yi et al., 2004). We have demonstrated that CYP2J2 specific inhibitors can block tumor proliferation and metastasis in vivo and in vitro (Chen et al., 2009).

Our evidence suggests a synergistic effect of ATO and C26. The combination of C26 and ATO appeared to have more than an additive effect on tumor cell apoptosis than the individual treatments. In addition, the combined effect of C26 and ATO could be attenuated after EET or NAC pretreatment. Thus, the synergistic effect of C26 with ATO is through the inhibition EET synthesis and subsequent reduction in cellular antioxidant capacity. This is the first finding that EETs play important roles in tumor cell proliferation and apoptosis via oxidant stress. This adds
to the known antiapoptotic effects of EETs via enhancing Akt, MAPK1/2 signaling and regulating expression of apoptosis-related proteins Bcl-2/Bax (Chen et al., 2001; Yang et al., 2007). These effects are distinct from ATO mediated pathways, and therefore the combination of CYP2J2 inhibitor C26 with ATO may result in synergistic apoptotic effects. The present study suggests a novel strategy for treatment of human cancers. Enhanced apoptosis of arsenic-resistant tumor cells may be achieved by combined treatment with relatively low dosage of C26 and clinical acceptable dosage of ATO.

The results of the present study show for the first time that EETs increase antioxidant enzyme expression and activity in cancer cells. This effect enables tumor cells to resist the oxidative damage and the subsequent apoptosis induced by ATO. Moreover, by acting in synergy with ATO to cause tumor cell apoptosis, the CYP2J2 specific inhibitor C26, may be a promising molecule for clinical application. Further investigation of selective CYP2J2 inhibitors in anti-cancer therapies is warranted.
Acknowledgments

Liu Liu, Chen Chen and Wei Gong equally contributed to this work. We thank Drs. Dongdong Yu and Leya He for their help in analyzing the flow cytometry results.
Authorship Contribution

Participated in research design: Liu, Chen, and Wang.

Conducted experiments: Liu, Chen, Gong, and Li.

Performed data analysis: Liu, Chen, and Wang.

Wrote or contributed to the writing of the manuscript: Liu, Chen, Edin, Zeldin, and Wang.
References


Davison K, Mann KK, Waxman S and Miller WH, Jr. (2004) JNK activation is a


Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS and Liao JK (2002) Inhibition of vascular smooth muscle cell migration by cytochrome p450


Footnotes

This work was supported by the China Natural Science Foundation Committee grant [Grant 30700377, 30770882, 30430320]; the 973 Project [Grant 2007CB512004] and the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences [Grant Z01 ES025034].

To whom receive the reprint requests:
Dao Wen Wang, MD, PhD
Department of Internal Medicine
Tongji Hospital, Tongji Medical College
Huazhong University of Science and Technology
1095# Jiefang Ave.
Wuhan, 430030, P.R.China
Tel and Fax: (86-27)8366-3280
E-mail: dwwang@tjh.tjmu.cn

1Liu Liu, 2Chen Chen, 3Wei Gong, 4Yuanjing Li, 5Matthew L. Edin, 6Darryl C. Zeldin and 7Dao Wen Wang
Figure legends

**Scheme 1.** The hypothesis of the functions of EETs in tumor cell apoptosis induced by ATO.

**Figure 1.** Effect of EETs on the ROS production in ATO-treated Tca-8113 cells. Cells were pre-incubated with 100 nM EETs or vehicle for 24 hours, then exposed to 10 µM ATO for 2 hours. DCFH-DA was then incubated with cells at 37°C for 15 min to detect ROS. A) Quantification of mean ROS levels in Tca-8113 cells after ATO and EETs treatment. B) Representative flow cytometric histogram of DCF fluorescent levels. C) Quantification of mean ROS levels in Tca-8113 cells after ATO and 11,12-EET treatment (n= 3); D and E) Production of hydrogen peroxide measured by Amplex Red (n=6). Results shown are mean ± SEM; *p < 0.05 versus control; ** p<0.05 vs. ATO treatment alone.

**Figure 2.** Effect of 11,12-EET on anti-oxidant enzyme expression and activity. A) Anti-oxidant enzyme expression after 11,12-EET treatment for indicated time and dose. B) Total SOD and catalase activity. Tca-8113 cells were pre-incubated with 100 nM 11,12-EET for 12 hours and enzymatic activities were then measured. Results are shown as percent of control ± SEM. *p < 0.05 versus control.

**Figure 3.** 11,12-EET inhibition of ATO-induced mitochondrial impairment. A) Flow cytometric analysis of Tca-8113 cells treated with ATO (10 µM) and 11,12-EET (100 nM) for 24h using Annexin V-FITC and propidium iodide (PI) staining. The lower left quadrant represents non-apoptotic cells; the lower right quadrant represents early apoptotic cells (Annexin V positive, PI negative); and the upper right quadrant represents late apoptotic or necrotic cells (Annexin V and PI positive). B) Graph represents the mean percentage of Annexin V positive Tca-8113 cells expressed as the proportion of positive cells in each group (n=3). C) Detection of the mitochondrial...
transmembrane potential collapse by JC-1 staining. In cells with normal mitochondrial function, membrane potential–driven accumulation of these dyes results in the formation of red fluorescent J-aggregates as shown in the control panel. In cells treated with ATO, the green mitochondria stained with JC-1 dye indicate depressed $\Delta\Psi_m$. 

D) Caspases-3 and -9 activities in Tca-8113 cells. Cells were treated with 10 $\mu$M of ATO and 100 nM of 11,12-EET for 24 hours, lysed, and analyzed spectrophotometrically for caspase activity. 

E) Cytochrome c release in Tca-8113 cells. Cells were treated with 10 $\mu$M of ATO and 100 nM of 11,12-EET for 24 hours, lysed, and cytosolic protein were analyzed by western-blot. Data is reported as mean absorption relative to control ± SEM (n=5). * $p<0.05$ versus control; ** $p<0.05$ vs. ATO treatment alone.

**Figure 4.** 11,12-EET suppression of ATO-induced p38 and JNK activation. Cells were starved overnight, preincubated with 11,12-EET or p38/JNK inhibitor for 12h, and incubated with ATO or $H_2O_2$ for 15min. Data are representative of 3 independent experiments. Results shown are mean ± SEM (n=3); A and B) p38 and JNK activation in Tca-8113 cells treated with ATO (10 $\mu$M), 11,12-EET (100 nM) and $H_2O_2$ (200 $\mu$M) as indicated. C and D) Flow cytometric analysis of Tca-8113 cells treated with p38 inhibitor (20 $\mu$M) as indicated for 24h using Annexin V-FITC and propidium iodide (PI) staining. E and F) Flow cytometric analysis of Tca-8113 cells treated with JNK inhibitor (50 $\mu$M) as indicated for 24h using Annexin V-FITC and propidium iodide (PI) staining. * $p<0.05$ versus control, ** $p<0.05$ versus ATO. # $p<0.05$ versus ATO+EET or ATO+p38/JNK Inhibitor.

**Figure 5.** Effect of CYP2J2 inhibitor on cell proliferation. Cells were treated with the indicated drugs for 24 hours, and cell number was measured by the SRB assay. A) Effect of C26 on number of tumor cells. B) Effect of ATO on number of
tumor cells. C) Effect of combination of C26, ATO, 11,12-EET and NAC on tumor cells number. Cells were incubated with 2 μM of ATO, 1 μM of C26, 100 nM 11,12-EET and/or 2 mM of NAC, as indicated for 24 hours. Data are expressed as percent of untreated controls ± SEM (n=5); *p<0.05 versus control, **p<0.05 versus ATO+C26.

Figure 6. Effects of CYP2J2 inhibition on sensitization of tumor cells to ATO-induced ROS production and apoptosis. Tca-8113 cells were incubated with 2 μM of ATO, 1 μM of C26, 100 nM 11,12-EET and/or 2 mM NAC. A) Tca-8113 cells were preincubated with C26 and NAC for 1 h, followed by 24 hours incubation with 11,12-EET, 2 hours prior to detection, ATO was added to induce ROS. Production of hydrogen peroxide was measured by Amplex Red. Results shown are mean ± SEM (n= 6). B) Tca-8113 cells were preincubated with C26 and NAC for 1 h, and then EET and ATO were added for 24 hours. Density plots of Annexin V/PI staining measured by flow cytometry. C) Graph represents the mean number of Annexin V positive Tca-8113 cells expressed as percent of control untreated cells ± SEM (n=3). Each sample was run in duplicate, and the data is representative of 3 independent assays. D) Tca-8113 cells were treated with CYP2J2 specific siRNA (100nM) for 24h. CYP2J2 expression was determined by western-blot (n=3). E) Tca-8113 cells were treated with CYP2J2 specific siRNA (100nM), EET and ATO for 24 hours. Density plots of Annexin V/PI staining for apoptosis measured by flow cytometry. F) Graph represents the mean number of Annexin V positive Tca-8113 cells expressed as percent of control untreated cells ± SEM. Each sample was run in duplicate, and the data is representative of 3 independent assays. *p<0.05 versus control, **p<0.05 versus ATO+C26.
Scheme 1

11,12-EET → SODs → ROS → ATO → Mitochondrial dysfunction → Caspases3,9 → Apoptosis

11,12-EET → Catalase → ROS → P38, JNK → Apoptosis
Fig 3

A

B

C

D

E

Cytochrome c (cytosolic)
COX-IV (cytosolic)
Cytochrome c (mitochondrial)
COX-IV (mitochondrial)
β-actin (cytosolic)
Fig 5

A

**Tca-8113 cells**

<table>
<thead>
<tr>
<th>C26 (μM)</th>
<th>0</th>
<th>0.1</th>
<th>0.5</th>
<th>1</th>
<th>5</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell viability (%) of control</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>90</td>
<td>80</td>
</tr>
</tbody>
</table>

**HepG2 cells**

<table>
<thead>
<tr>
<th>C26 (μM)</th>
<th>0</th>
<th>0.1</th>
<th>0.5</th>
<th>1</th>
<th>5</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell viability (%) of control</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>80</td>
<td>80</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>ATO (μM)</th>
<th>0</th>
<th>2</th>
<th>5</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell viability (%) of control</td>
<td>100</td>
<td>100</td>
<td>90</td>
<td>80</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ATO (μM)</th>
<th>0</th>
<th>2</th>
<th>5</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell viability (%) of control</td>
<td>100</td>
<td>100</td>
<td>90</td>
<td>80</td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th>Condition</th>
<th>Cell Viability (%) of control</th>
<th>CON</th>
<th>C26</th>
<th>ATO</th>
<th>EET</th>
<th>ATO+C26</th>
<th>EET</th>
<th>ATO+C26+HAC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100</td>
<td>100</td>
<td>90</td>
<td>80</td>
<td>90</td>
<td>80</td>
<td>90</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Condition</th>
<th>Cell Viability (%) of control</th>
<th>CON</th>
<th>C26</th>
<th>ATO</th>
<th>EET</th>
<th>ATO+C26</th>
<th>EET</th>
<th>ATO+C26+HAC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100</td>
<td>100</td>
<td>90</td>
<td>80</td>
<td>90</td>
<td>80</td>
<td>90</td>
</tr>
</tbody>
</table>